Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And what that has translated into a strong demand for testing broad and deep adoption |
| In summary, we are very pleased with our first full quarter of commercial performance |
| And we've had strong interest and feedback from that community |
| That being said, the duration of therapy that we are seeing overall, and particularly in the patients with a confirmed response, really suggests a meaningful benefit to patients |
| And so -- with those factors in mind, our team has done an excellent job executing both prior to approval as it relates to education of the market and then post approval and really becoming and establishing ourselves as a valued partner to the ovarian cancer community |
| And obviously, one of the points that we just want to make here is that our largest accounts are our academic accounts and the uptake there has been very strong |
| We are very pleased with this performance and believe these results reflect early and accelerated recognition of the benefits ELAHERE brings to an advanced ovarian cancer population with high unmet need |
| We were also excited to receive resoundingly positive physician feedback on ELAHERE at the conference |
| We continue to see strong demand for the FOLR1 diagnostic through our four central labs set up in collaboration with Roche |
| Right now, I think the community has come in stronger than we anticipated |
| And I'm also going to offer my congratulations on a very well-executed first quarter sales here for ELAHERE |
| We've been pleased to see the impact of these interactions, with broader-than-anticipated uptake among target accounts, particularly in the community setting |
| We are very proud of the work our medical affairs team has done in this area |
| We've made a very strong start to 2023 exemplified by the Q1 revenue for ELAHERE, the advancement of our clinical programs for four novel ADCs and the strengthening of our balance sheet by securing a non-dilutive credit facility with Pharmakon for up to $175 million |
| We are very pleased with the start we've made with ELAHERE and partnership that we're building with the ovarian cancer community |
| Regarding access, we are very pleased with how quickly payers have included ELAHERE and coverage policies aligned to our label |
| I would also like to welcome Isabel Kalofonos, who joined us on Monday to drive the continued success of ELAHERE leading our high-performing commercial organization |
| And so we see that with the uptake in testing, which continues to be very robust |
| Bears repeating that this is the first new drug specifically approved for platinum resistant ovarian cancer in almost a decade, 75% of these patients receive single-agent chemotherapy, which is characterized by low overall response rates with short duration and significant side effects, which really leads us to the second factor, which is the product profile for ELAHERE where we see a meaningful improvement over the standard of care with upwards of 3x in terms of the overall response rates and a manageable safety profile |
| But just to be clear, the uptake there is ahead of our expectations and they are in fact our largest customers |
| The testing up to this point has been very robust |
| And as Mark had mentioned, we also had a nice foundation given prior therapeutics in the space |
| On that note, building on a fast start to close 2022, our teams made notable progress across all four launch imperatives, as we work to position ELAHERE as the standard of care for folate receptor alpha positive ovarian cancer |
| And let me add my congratulations on excellent results |
| They're hoping for stable disease and they want to give their patients drugs that are well tolerated |
| What I will say is, we do see both monotherapy and combination use in the database, which is of course encouraging to us, but can't comment any further with any conviction |
| So, what we can see are the accounts that are ordering have a very healthy percentage of new accounts coming online and a significant percentage of repeat orders |
| You will appreciate that it's growing and continues to grow |
| And so we've been able to ride on the back of that |
| So Mark mentioned, testing has been very well received |
| Statement |
|---|
| And in fact it may be that these patients will do worse than they would have again in the pre-PARP era |
| Physicians are quickly acclimating to it and we've seen very little pushback on the testing requirements |
| And so, it's difficult to sort of articulate any conviction around trends and so on |
| We know these patients unfortunately have cross resistance to these agents that damage DNA |
| I will say just to allay any concerns that we see continued momentum and continued growth of the product in April but we're going to stay away from that |
| And I think it's safe to say that it will not continue to scale linearly |
| In terms of the market uptake John, this will be a little bit of a recurring theme on this call which is we've got very limited data at this point |
| So that actually is impacting what our thoughts are around expectations for available therapy |
Please consider a small donation if you think this website provides you with relevant information